Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V81444 PET and fMRI Study in Healthy Volunteers
NCT02764892Phase 1Completed
- Sponsor
- Vernalis
- Start
- Aug 2012
- Primary completion
- Nov 2012
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of ciforadenant in Parkinson's disease (PD), sponsored by Vernalis. Primary endpoint: Plasma concentration V81444 corresponding with 50% brain A2A receptor occupancy at 27 hours. Started Aug 2012; status: completed.
02
Drugs
ciforadenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02764892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02764892.